share_log

R&G PharmaStudies Co., Ltd.'s (SZSE:301333) Market Cap Dropped CN¥422m Last Week; Individual Investors Who Hold 51% Were Hit as Were Institutions

上場企業R&G PharmaStudies株式会社(SZSE:301333)の時価総額は先週CN¥422m下落しました。個人投資家も、株式の51%を所有している機関投資家も被害を受けました。

Simply Wall St ·  03/07 18:31

Key Insights

  • R&G PharmaStudies' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 3 shareholders own 53% of the company
  • 14% of R&G PharmaStudies is held by insiders

Every investor in R&G PharmaStudies Co., Ltd. (SZSE:301333) should be aware of the most powerful shareholder groups. With 51% stake, private companies possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

While the holdings of private companies took a hit after last week's 8.8% price drop, institutions with their 16% holdings also suffered.

Let's delve deeper into each type of owner of R&G PharmaStudies, beginning with the chart below.

ownership-breakdown
SZSE:301333 Ownership Breakdown March 7th 2024

What Does The Institutional Ownership Tell Us About R&G PharmaStudies?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that R&G PharmaStudies does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at R&G PharmaStudies' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
SZSE:301333 Earnings and Revenue Growth March 7th 2024

R&G PharmaStudies is not owned by hedge funds. Ace Union Holding Limited is currently the company's largest shareholder with 29% of shares outstanding. With 12% and 12% of the shares outstanding respectively, Hongbei Zheng and Shihezi Kangyunfu Equity Investment Co., Ltd. are the second and third largest shareholders.

After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is some analyst coverage of the stock, but it could still become more well known, with time.

Insider Ownership Of R&G PharmaStudies

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

It seems insiders own a significant proportion of R&G PharmaStudies Co., Ltd.. Insiders have a CN¥595m stake in this CN¥4.4b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 7.2% stake in R&G PharmaStudies. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Private Company Ownership

We can see that Private Companies own 51%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand R&G PharmaStudies better, we need to consider many other factors.

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする